0.15%盐酸苄胺和0.5%氯化十六烷基吡啶复合口服喷雾剂的体外抗菌活性。

IF 2.8 Q2 Pharmacology, Toxicology and Pharmaceutics

Drugs in Context Pub Date : 2025-09-29 eCollection Date: 2025-01-01 DOI:10.7573/dic.2024-9-3

Alessandra Capezzone de Joannon, Maren Eggers, Luigi Boltri

{"title":"0.15%盐酸苄胺和0.5%氯化十六烷基吡啶复合口服喷雾剂的体外抗菌活性。","authors":"Alessandra Capezzone de Joannon, Maren Eggers, Luigi Boltri","doi":"10.7573/dic.2024-9-3","DOIUrl":null,"url":null,"abstract":"Background: Reducing the microbial load in the upper respiratory tract can reduce the risk of transmission and spread of respiratory tract infections.Methods: The in vitro antimicrobial activity of a new oral spray combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride (Tantum Verde DUO®, Angelini Pharma S.p.A., spray duo) was investigated.Results: Spray duo showed bacterial, yeasticidal and virucidal activity against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae (1 minute contact), Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes (30 second contact), Candida albicans (5 minute contact), modified vaccinia Ankara (3 minute contact), influenza A virus subtype H1N1, herpes simplex virus 1, and SARS-CoV-2 (1 minute contact).Conclusions: Spray duo showed antimicrobial activity under in vitro conditions. Further investigations are warranted to evaluate the antimicrobial activity in clinical practice.","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503868/pdf/","citationCount":"0","resultStr":"{\"title\":\"In vitro antimicrobial activity of an oral spray combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride.\",\"authors\":\"Alessandra Capezzone de Joannon, Maren Eggers, Luigi Boltri\",\"doi\":\"10.7573/dic.2024-9-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Reducing the microbial load in the upper respiratory tract can reduce the risk of transmission and spread of respiratory tract infections.Methods: The in vitro antimicrobial activity of a new oral spray combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride (Tantum Verde DUO®, Angelini Pharma S.p.A., spray duo) was investigated.Results: Spray duo showed bacterial, yeasticidal and virucidal activity against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae (1 minute contact), Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes (30 second contact), Candida albicans (5 minute contact), modified vaccinia Ankara (3 minute contact), influenza A virus subtype H1N1, herpes simplex virus 1, and SARS-CoV-2 (1 minute contact).Conclusions: Spray duo showed antimicrobial activity under in vitro conditions. Further investigations are warranted to evaluate the antimicrobial activity in clinical practice.\",\"PeriodicalId\":11362,\"journal\":{\"name\":\"Drugs in Context\",\"volume\":\"14 \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503868/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in Context\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7573/dic.2024-9-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2024-9-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

背景：减少上呼吸道微生物负荷可以降低呼吸道感染的传播和扩散风险。方法：对0.15%盐酸苄胺与0.5%氯化十六烷基吡啶复合的新型口服喷雾剂（Tantum Verde DUO®，Angelini Pharma S.p.A, spray DUO）的体外抗菌活性进行研究。结果：喷雾对金黄色葡萄球菌、铜绿假单胞菌、大肠杆菌、丙型肠球菌（接触1分钟）、流感嗜血杆菌、卡他莫拉菌、化脓性链球菌（接触30秒）、白色念珠菌（接触5分钟）、改性安卡拉痘苗（接触3分钟）、甲型H1N1流感病毒亚型、单纯疱疹病毒1型和SARS-CoV-2（接触1分钟）均有杀菌、杀酵母和杀病毒活性。结论：在体外条件下，双喷菌具有良好的抑菌活性。需要进一步的研究来评估临床实践中的抗菌活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In vitro antimicrobial activity of an oral spray combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride.

Background: Reducing the microbial load in the upper respiratory tract can reduce the risk of transmission and spread of respiratory tract infections.

Methods: The in vitro antimicrobial activity of a new oral spray combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride (Tantum Verde DUO^®, Angelini Pharma S.p.A., spray duo) was investigated.

Results: Spray duo showed bacterial, yeasticidal and virucidal activity against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae (1 minute contact), Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes (30 second contact), Candida albicans (5 minute contact), modified vaccinia Ankara (3 minute contact), influenza A virus subtype H1N1, herpes simplex virus 1, and SARS-CoV-2 (1 minute contact).

Conclusions: Spray duo showed antimicrobial activity under in vitro conditions. Further investigations are warranted to evaluate the antimicrobial activity in clinical practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.